Liquidia revenue surpasses $170 million in Q2

• Liquidia reported Q2 2026 revenue of $171.7 million, driven by YUTREPIA net product sales of $170.4 million.
• The company recorded net income of $74.7 million and adjusted EBITDA of $96.3 million, marking its fourth consecutive profitable quarter.
• Liquidia expanded YUTREPIA adoption with more than 5,000 patients starting treatment since launch and raised cash reserves to $284.2 million.

Liquidia (NASDAQ:LQDA) reported second-quarter 2026 revenue of $171.7 million, compared with $8.8 million a year earlier, driven mainly by YUTREPIA net product sales of $170.4 million.

The company’s YUTREPIA sales increased 31% from the first quarter of 2026, marking the fourth consecutive quarter of profitability since the product launch.

Liquidia reported net income of $74.7 million and non-GAAP adjusted EBITDA of $96.3 million in Q2 2026, while cash and cash equivalents increased to $284.2 million at June 30, 2026.

Since its June 2025 launch, YUTREPIA has received approximately 5,900 unique prescriptions, with more than 5,000 patients starting treatment and prescription-to-start conversion above 85%.

Liquidia also reported more than 1,100 prescribers using YUTREPIA and said it is advancing 10 clinical studies involving YUTREPIA and L606, its investigational inhaled liposomal treprostinil formulation.

The company develops treatments for pulmonary hypertension and related conditions, with YUTREPIA designed as an inhaled treprostinil therapy for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.